Candidamycosis in Gynaecology

  • H. Van der Pas
Part of the Federation of European Microbiological Societies Symposium Series book series (FEMS, volume 50)


Despite Wilkinson’s description of Candida as a causative agent of fungal vaginitis already in 1849 in The Lancet, it is still a current topic in medical literature.


Candida Albicans Oral Therapy Protease Production Topical Therapy Brilliant Green 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    F.C. Odds, “Candida and Candida Vaginitis”, Baltimore University Park Press, Baltimore (1979).Google Scholar
  2. 2.
    F.C. Odds, Candidosis of the genitalia, in: “Candida and Candidosis”, 2nd. ed., pp. 124–135, Baillière Tindall Publishers, London (1988).Google Scholar
  3. 3.
    J.D. Sobel, Pathogenesis of vaginal conditions, in: “Oral therapy in vaginal condiditons”, pp. 1–11, The Medicine Publishing Foundation, Oxford (1985).Google Scholar
  4. 4.
    J.D. Sobel, Epidemiology and pathogenesis of recurrent vulvovaginal conditions, Am. J. Obstet. Gynaecol., 152: 924 (1985).Google Scholar
  5. 5.
    M.P.J.M. Bisschop, J.M.W.M. Merkus, H. Scheijgrond, J. Van Cutsem and A. Van de Kuy, Treatment of vaginal candidosis with ketoconazole, a new orally active antimycotic, Eur. J. Obstet. Gynaecol Reprod. Biol., 9: 253 (1979).CrossRefGoogle Scholar
  6. 6.
    M.P.J.M. Bisschop, J.M.W.M. Merkus, and J. Van Cutsem, The influence of antibiotics on the growth of Candida albicans in the vagina, Eur. J. Obstet. Gynaecol. Reprod. Biol., 20: 113 (1985).CrossRefGoogle Scholar
  7. 7.
    J.D. Sobel, New insights into the pathogenesis of vaginal conditions, in: “Vaginal Conditions and Oral Antifungal Therapy”, Proceedings of a Satellite Symposium to te IVth International Workshop for Infections in Gynaecology and Obstetrics, Munich (in press).Google Scholar
  8. 8.
    P.J.H. Tooley, Patient and doctors preferences in the treatment of vaginal conditions, Practitioner, 229: 655 (1985).PubMedGoogle Scholar
  9. 9.
    J. Van Cutsem, F. Van Gerven and P.A.J. Janssen, Activity of orally, topically and parenterally administered itraconazole in the treatment of superficial and deep mycoses: Animal models, Rev. Infect. Dis., 9: 15 (1987).CrossRefGoogle Scholar
  10. 10.
    J. Heykants, M. Michiels and W. Meuldermans, The pharmacokinetics of itraconazole in animals and man: an overview, in:“Recent Trends in the Discovery Development and Evaluation of Antifungal Agents”, R.A. Fromtling, ed., pp.251–263, J.R. Prous Science Publishers, Barcelona (1987).Google Scholar
  11. 11.
    G. Cauwenbergh, Itraconazole: the first active antifungal for single-day treatment of vaginal candidosis, Cur Ther. Res., 41: 210 (1987).Google Scholar
  12. 12.
    K. Lavrijssen, J. Van Houdt, D. Thijs, W. Meuldermans, and J. Heykants, Induction potential of antifungals containing an imidazole or triazole moiety. Miconazole and ketoconazole, but not itraconazole are able to induce hepatic drug metobilizing enzymes of male rats at high doses, Biochem. Pharmacol., 35: 1867 (1986).CrossRefGoogle Scholar
  13. 13.
    K. Lavrijssen, J. Van Houdt, D. Van Dijk, W. Meuldermans, and J. Heykants, Study on the induction and/or inhibition potential of itraconazole and fluconazole towards drug-metabolizing enzymes in the liver of the mouse. Preclin. Res. Report R 51 211/58, Jansen Pharmaceutica, Beerse, Belgium (1988).Google Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • H. Van der Pas
    • 1
  1. 1.Department of Obstetrics and GynecologyUniversity of Ghent and St. Elisabeth HospitalTurnhoutBelgium

Personalised recommendations